Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.
Treatment with opioid analgesics often causes adverse reactions that may make continuous use of such drugs difficult. We investigated the efficacy and safety of controlled-release oxycodone in the treatment of gynecologic cancer pain. The patients included 14 with cervical cancer, 6 with corpus cancer, and 17 with ovarian cancer. Treatment with controlled-release oxycodone was started at 5 mg/dose when pain control using nonsteroidal anti-inflammatory drugs became ineffective. The dose was titrated to the optimal level over a mean duration of 2.34 +/- 1.13 days, and the initially optimal dose was 18.92 +/- 5.23 mg/day. Although no patients experienced confusion, vomiting, or respiratory depression, 17 patients experienced adverse events, including constipation in 14 patients and nausea in 9 patients. The incidence of nausea was low in patients receiving oxycodone and prochlorperazine. In the present study, patients with moderate to severe pain caused by gynecologic cancer could successfully be treated with controlled-release oxycodone.
Suzuki
Takahiro
T
Department of Obstetrics and Gynecology, Sapporo Medical University, School of Medicine, Sapporo, Japan. tsuzuki@sapmed.ac.jp
Morishita
Miyuki
M
Ito
Eiki
E
Matsuura
Motoki
M
Tanaka
Ryoichi
R
Saito
Tsuyoshi
T
D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications*; D010098:Oxycodone / Q000008:administration & dosage* / Q000009:adverse effects; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D002583:Uterine Cervical Neoplasms / Q000150:complications; D014594:Uterine Neoplasms / Q000150:complications*
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010098:Oxycodone